Chargement en cours...
Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
This post hoc analysis assessed the benefit–risk profile of esketamine nasal spray + oral antidepressant (AD) induction and maintenance treatment in patients with treatment‐resistant depression (TRD). The Benefit–Risk Action Team framework was utilized to assess the benefit–risk profile using data f...
Enregistré dans:
| Publié dans: | Clin Pharmacol Ther |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894501/ https://ncbi.nlm.nih.gov/pubmed/32860422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.2024 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|